FLT3 and acute myeloid leukemia: Because FLT3 TKIs are increasingly being used as frontline therapy for FLT3-mutated AML, it is important to understand the degree to which prior TKI therapy alters the likelihood of response or survival benefit conferred by gilteritinib in R/R FLT3-mutated AML.